| Popis: |
Introduction/Background In this retrospective study, we investigated the ovarian function of 69 premenopausal patients with hormone-receptor positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer receiving tamoxifen with a focus on the management and survival of patients with ovarian cyst formation. Methodology 69 premenopausal women treated with tamoxifen for early primary HER2- negative breast cancer - referred to the gynaecology ultrasound department of the university hospitals of Leuven between 2003 and 2018 - were selected. Patients that received chemotherapy, adjuvant radiotherapy or ovarian suppression were excluded. Oncological data, gynaecological ultrasound reports, details on menstruation pattern during tamoxifen and hormonal blood tests were obtained from patient records. Results In total, 31 patients developed a cyst during tamoxifen treatment. Median age at diagnosis of breast cancer was 47 years (37–53) and younger patients were more likely to develop ovarian cysts (p 400 pg/ml) while treated with tamoxifen. Survival of all patients was excellent; with a median follow-up of 73 months no events occurred. Conclusion We reported that the administration of tamoxifen in premenopausal women is associated with ovarian cyst formation and high estradiol levels. Ovarian cysts mostly can be managed conservatively. In this series, the impact of tamoxifen on ovarian function does not appear to affect survival. Disclosure Nothing to disclose. |
